Launch and Pricing of a €750m Bond


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO
WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

AstraZeneca launches and prices a €750,000,000 7 year bond issue

AstraZeneca PLC, rated A2 (stable outlook) by Moody's and AA- (negative outlook)
by Standard & Poor's, announces today the successful pricing of euro medium term
notes in an aggregate principal amount of €750,000,000 maturing on 24 November
2021 with a coupon of 0.875% (the "Notes").

The proceeds of the issue will be used to fund the repayment of outstanding euro
medium term notes in an aggregate principal amount of €750,000,000 maturing in
January 2015.

The Notes are being issued under the U.S.$5,000,000,000 Euro Medium Term Note
Programme of AstraZeneca PLC.

The Notes will be issued to institutional investors outside the US in accordance
with Regulation S of the U.S. Securities Act of 1933, as amended. The Notes will
be admitted to listing on the UK Listing Authority's Official List and to
trading on the London Stock Exchange's regulated market.

Notes to editors

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com.

Attachments

11191181.pdf